Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Aptose Biosciences ( (TSE:APS) ) is now available.
Aptose Biosciences announced the dosing of the first patients in the TUSCANY Phase 1/2 trial, which explores tuspetinib in combination with venetoclax and azacitidine as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) patients. This triplet therapy aims to address diverse AML populations and improve response rates and survival while minimizing toxicities, potentially expanding its application to a broader range of AML patients.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines to address unmet medical needs in oncology, with an emphasis on hematology. Their lead clinical-stage product, tuspetinib (TUS), is an oral kinase inhibitor that has shown activity as monotherapy and in combination therapy for patients with relapsed or refractory acute myeloid leukemia (AML) and is now being developed as a frontline triplet therapy for newly diagnosed AML.
YTD Price Performance: -11.25%
Average Trading Volume: 6,633,550
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $12.98M
For an in-depth examination of APS stock, go to TipRanks’ Stock Analysis page.
